LiDCO Group Plc 25 October 2005 For immediate release 25 October 2005 LIDCO GROUP PLC ("LiDCO" or "the Company") CLINICAL ADVISORY BOARD APPOINTMENT 25 October 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that Professor Michael R. Pinsky, has joined its Clinical Advisory Board. Professor Pinsky is Professor of Critical Care Medicine, Bioengineering and Anesthesiology at the University of Pittsburgh School of Medicine, USA and is a member of the editorial board of the American Journal of Respiratory and Critical Care Medicine, Intensive Care Medicine, Journal of Critical Care and Critical Care Forum. He is editor-in-chief of the eMedicine textbook Critical Care Medicine. He has a wide range of research interests - among them being the study of heart-lung interactions, hemodynamic monitoring, cardiovascular physiology, sepsis and outcomes research. He is a world leading authority on the application of both existing invasive, and the more recent minimally invasive, monitoring technologies to optimise cardiovascular physiology and thereby improve outcomes in critically ill patients. Dr Terry O'Brien, LiDCO's Chief Executive, commented: "I am delighted to welcome Prof Michael Pinsky to our Clinical Advisory Board. Michael is internationally renowned for his work on functional hemodynamic monitoring and its application to the care of critically ill patients. His combination of clinical and research experiences will make a significant contribution to the evolution of LiDCO's future product development strategy." Prof Michael Pinsky commented: "I am very pleased to be associated with LiDCO and their innovative technology. I believe that their ability to apply cutting edge technologies coupled with our evolving understanding of the interaction between disease and treatment will result in novel and effective treatment protocols. The adoption of technology such as LiDCO's will be a key factor in improving patient outcomes in a cost-effective fashion." For further information please contact: LiDCO Group Plc Terry O'Brien (CEO) terry@lidco.com 020 7749 1500 Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.com Buchanan Communications Tim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Panmure Gordon Aubrey Powell, Katherine Roe 020 7459 3600 Notes for Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base. The Company's manufacturing facility is in Hoxton, London and its current products are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitor accurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets in Europe, the USA, Brazil and Japan. It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care - (EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO's minimally invasive monitoring technology were presented during the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels (21st to 25th March) and the full paper will be published on November 8th in Critical Care Medicine. The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62 patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissue oxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange